Breast cancer orthotopic

products-servicesPharmatest Services Ltd
June 11th 2014

Pharmatest’s orthotopic breast cancer models are suitable for testing the efficacy of drug compounds against primary tumor growth and dissemination. They involve inoculation of breast cancer cells into the mammary fat pad, leading to development of a primary mammary tumor to the site of inoculation.

Description

The major advantage of using orthotopic models is maintenance of the proper tissue microenvironment that is known to affect tumor growth, metastasis and drug resistance.

Pharmatest offers orthotopic breast cancer models based on human estrogen receptor positive or triple negative breast cancer cells. Alternatively, models are based on mouse triple negative cancer cells.

The growth of the tumor is monitored by measuring the dimensions of the tumor at desired intervals during the experiment. At the end of the experiment the animals are euthanized and the primary tumor and selected organs are collected for further analysis.

In the case of the triple negative cell lines, metastasis to various distant sites, such as lungs, can also be rapidly determined by ex vivo fluorescence imaging.

Resources

Click on breast cancer orthotopic models for other information.
Click on Pharmatest to contact the company directly.


Supplier Information
Supplier: Pharmatest Services Ltd
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com